EUVIMEDEUVIMED entdecken
Crossref

Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database

Fatemeh Ahmadi, Niaz Chalabianloo, Eric McArthur, Mohammad Ali Omrani iD, Sheikh S Abdullah, Facundo Garcia-Bournissen, Flory T Muanda iD

Annals of Pharmacotherapy · 2025

DOI: 10.1177/10600280251320690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Fatemeh Ahmadi und 6 weiteren Autor:innen. Beteiligte Einrichtung: ICES, London, ON, Canada. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Bacterial Agents, Respiratory Distress Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The US Food and Drug Administration (FDA) has raised concerns about a potential link between trimethoprim/sulfamethoxazole (TMP-SMX) and an increased risk of acute respiratory failure/acute respiratory distress syndrome (ARF/ARDS) in healthy adolescents and young adults.

Objective

To assess the association between TMP-SMX and the risk of ARF/ARDS using data from the FDA Adverse Event Reporting System (FAERS).

Methods

We analyzed adverse drug events (ADEs) reported in FAERS from January 1, 2004, to December 31, 2023. We focused on reports where TMP-SMX, amoxicillin-clavulanic acid, or azithromycin were the primary suspect drugs for ADEs in individuals aged 10 to 24 years. The outcomes of interest—ARF/ARDS—were identified using MedDRA-preferred terms. We used an active comparator-restricted disproportionality analysis (ACR-DA) to estimate the reporting odds ratio (ROR) and 95% confidence interval (CI), adjusting for age, sex, acne, and urinary tract infections. Bayesian Confidence Propagation Neural Networks (BCPNN) were used to calculate the Information Components (IC 025 ). Due to the amount of missing information, a case-by-case analysis could not be performed.

Results

3171 ICSRs (810 for TMP-SMX, 1617 for azithromycin, and 744 for amoxicillin-clavulanic acid) were included in the study. ACR-DA showed an unadjusted 8-fold increase in the reports of ARF/ARDS with TMP-SMX compared with azithromycin (unadjusted ROR, 7.98; 95% CI, 4.09 to 15.60) and an adjusted 3-fold increase after adjustment for age, sex, acne, and urinary tract infection (adjusted ROR, 2.80; 95% CI, 1.28 to 6.11). BCPNN analysis confirmed significant disproportionality (IC 025 , 0.75). No cases of ARF/ARDS were reported for amoxicillin-clavulanic acid. Conclusion and Relevance: TMP-SMX may increase the risk of ARF/ARDS, requiring further validation in larger pharmacoepidemiological studies. Our findings lay the groundwork for future research to further investigate the safety profile of TMP-SMX in adolescent populations. If confirmed, prescribers should exercise greater caution when prescribing TMP-SMX to adolescents and young adults.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsRespiratory Distress SyndromeHumansAdolescentUnited StatesMaleYoung AdultFemaleUnited States Food and Drug AdministrationChildDatabases, FactualBayes Theorem

Stichwörter der Autor:innen

adverse drug eventsadverse drug reactions (ADRs)drug safetytrimethoprim-sulfamethoxazole

Substanzen

Trimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial Agents

Autor:innen und Institutionen

  • ICES, London, ON, Canada.
  • Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
  • Lawson Health Research Institute, London Health Sciences Centre, London, ON, Canada.
  • Division of Paediatric Clinical Pharmacology, Department of Paediatrics, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

ORCID-Profile: Mohammad Ali Omrani, Flory T Muanda

Zitieren

APA

Ahmadi, F., Chalabianloo, N., McArthur, E., Omrani, M. A., Abdullah, S. S., Garcia-Bournissen, F., & Muanda, F. T. (2025). Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251320690

Vancouver

Ahmadi F, Chalabianloo N, McArthur E, Omrani MA, Abdullah SS, Garcia-Bournissen F, et al. Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280251320690

BibTeX
@article{Ahmadi2025,
  author = {Ahmadi, Fatemeh and Chalabianloo, Niaz and McArthur, Eric and Omrani, Mohammad Ali and Abdullah, Sheikh S and Garcia-Bournissen, Facundo and Muanda, Flory T},
  title = {Severe Acute Respiratory Failure Associated With Trimethoprim/Sulfamethoxazole Among Adolescent and Young Adults: An Active Comparator-Restricted Disproportionality Analysis From the FDA Adverse Event Reporting System (FAERS) Database},
  journal = {Annals of Pharmacotherapy},
  year = {2025},
  doi = {10.1177/10600280251320690}
}
Kostenlos starten →